twoXAR, Inc., a Palo Alto, CA-based artificial intelligence (AI)-driven biopharmaceutical company, raised $10m in Series A financing.
The round was led by SoftBank Ventures, with participation from Andreessen Horowitz Bio Fund and OS Fund. With this financing, JP Lee, Managing Director at SoftBank Ventures, and Vijay Pande, PhD, General Partner at Andreessen Horowitz, have been appointed to the twoXAR Board of Directors.
The company will use the funds to build its drug pipeline through partnerships and accelerate preclinical development of existing candidates.
Led by Andrew A. Radin, co-founder and Chief Executive Officer, twoXAR uses its proprietary AI-driven platform to rapidly identify drug candidates for in vivo testing in weeks (rather than years) across therapeutic areas including diseases such as liver cancer, rheumatoid arthritis, and type 2 diabetes.
The company is building a pipeline of novel, proprietary drug candidates through partnerships with biopharmaceutical companies, drug developers, and investors.